G. Emons

617 total citations
19 papers, 357 citations indexed

About

G. Emons is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, G. Emons has authored 19 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Obstetrics and Gynecology, 10 papers in Reproductive Medicine and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G. Emons's work include Endometrial and Cervical Cancer Treatments (8 papers), Ovarian cancer diagnosis and treatment (7 papers) and Estrogen and related hormone effects (4 papers). G. Emons is often cited by papers focused on Endometrial and Cervical Cancer Treatments (8 papers), Ovarian cancer diagnosis and treatment (7 papers) and Estrogen and related hormone effects (4 papers). G. Emons collaborates with scholars based in Germany, Austria and Bulgaria. G. Emons's co-authors include Carsten Gründker, Volker Viereck, Lars Schlotawa, K.-D. Schulz, Karin Kast, S. Seitz, Olaf Ortmann, Martin Hellriegel, H. Madjar and H Prömpeler and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Human Reproduction.

In The Last Decade

G. Emons

19 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Emons Germany 9 197 137 106 89 77 19 357
Ioannis Dedes Switzerland 10 153 0.8× 116 0.8× 29 0.3× 119 1.3× 58 0.8× 24 329
Javier García-Ferreyra Peru 10 280 1.4× 102 0.7× 80 0.8× 107 1.2× 272 3.5× 19 532
Katarzyna Rainczuk Australia 11 117 0.6× 111 0.8× 33 0.3× 84 0.9× 55 0.7× 14 297
Paula Lee United States 3 100 0.5× 146 1.1× 18 0.2× 137 1.5× 97 1.3× 6 362
Terrence D. Lewis United States 9 234 1.2× 144 1.1× 26 0.2× 51 0.6× 80 1.0× 16 332
Peng-Hui Wang Taiwan 10 137 0.7× 81 0.6× 17 0.2× 83 0.9× 27 0.4× 17 269
Meaghan J. Griffiths Australia 9 132 0.7× 55 0.4× 26 0.2× 71 0.8× 148 1.9× 14 288
P.J. O'Donovan United Kingdom 6 47 0.2× 43 0.3× 98 0.9× 152 1.7× 22 0.3× 10 283
S I Wolf United States 6 183 0.9× 131 1.0× 17 0.2× 88 1.0× 21 0.3× 9 333
Baoxia Gu China 4 88 0.4× 106 0.8× 20 0.2× 64 0.7× 24 0.3× 6 238

Countries citing papers authored by G. Emons

Since Specialization
Citations

This map shows the geographic impact of G. Emons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Emons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Emons more than expected).

Fields of papers citing papers by G. Emons

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Emons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Emons. The network helps show where G. Emons may publish in the future.

Co-authorship network of co-authors of G. Emons

This figure shows the co-authorship network connecting the top 25 collaborators of G. Emons. A scholar is included among the top collaborators of G. Emons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Emons. G. Emons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Seitz, S., et al.. (2020). Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Archives of Gynecology and Obstetrics. 301(4). 875–884. 39 indexed citations
2.
3.
4.
Emons, G., Philipp Harter, Pauline Wimberger, et al.. (2014). Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors. International Journal of Gynecological Cancer. 24(2). 260–265. 47 indexed citations
5.
Wright, Emily M., et al.. (2012). Transvaginal Ultrasound for Endometrial Carcinoma Screening – Current Evidence-based Data. Geburtshilfe und Frauenheilkunde. 72(12). 1088–1091. 7 indexed citations
6.
Colomban, Olivier, M. Heywood, Margaret Davy, et al.. (2011). Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study.. Journal of Clinical Oncology. 29(15_suppl). 5065–5065. 1 indexed citations
7.
8.
Emons, G.. (2009). Endometriumkarzinom. Der Gynäkologe. 42(10). 799–811. 2 indexed citations
9.
Ackermann, Sarah E., MW Beckmann, Oumar Camara, et al.. (2007). Arbeitsgemeinschaft Gynäkologische Onkologie. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. Bern Open Repository and Information System (University of Bern). 1 indexed citations
10.
Günthert, Andreas R., S. Ackermann, MW Beckmann, et al.. (2006). Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. Gynecologic Oncology. 104(1). 86–90. 16 indexed citations
11.
Ackermann, S., Ludwig Kiesel, Eric Steiner, et al.. (2005). Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer, AGO Uterus-4. Journal of Clinical Oncology. 23(16_suppl). 5083–5083. 2 indexed citations
12.
13.
14.
Viereck, Volker, et al.. (2002). Diagnostik und Therapie der Uterussarkome. Zentralblatt für Gynäkologie. 124(11). 506–510. 1 indexed citations
15.
Heyl, W., et al.. (2002). Placenta percreta in week 10 of pregnancy with consecutive hysterectomy: Case report. Human Reproduction. 17(3). 817–820. 32 indexed citations
16.
Prömpeler, H, et al.. (2002). Value of sonomorphological criteria of the endometrium in women with postmenopausal bleeding: a multivariate analysis. Ultrasound in Obstetrics and Gynecology. 19(1). 62–68. 31 indexed citations
17.
Gründker, Carsten, Lars Schlotawa, Volker Viereck, & G. Emons. (2001). Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin. European Journal of Endocrinology. 145(5). 651–658. 31 indexed citations
18.
Emons, G. & K.-D. Schulz. (2000). Primary and Salvage Therapy with LH-RH Analogues in Ovarian Cancer. Recent results in cancer research. 153. 83–94. 24 indexed citations
19.
Günthert, Andreas R., et al.. (2000). Docetaxel is effective in the treatment of metastatic endometrial cancer.. PubMed. 19(4C). 3459–61. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ioannis Dedes Breakdown of academic impact, for papers by Javier García-Ferreyra Breakdown of academic impact, for papers by Katarzyna Rainczuk Breakdown of academic impact, for papers by Paula Lee Breakdown of academic impact, for papers by Terrence D. Lewis Breakdown of academic impact, for papers by Peng-Hui Wang Breakdown of academic impact, for papers by Meaghan J. Griffiths Breakdown of academic impact, for papers by P.J. O'Donovan Breakdown of academic impact, for papers by S I Wolf Breakdown of academic impact, for papers by Baoxia Gu
Rankless by CCL
2026